The Centre for Drug Research and Development (CDRD) announced today the signing of affiliation agreements with both the University of Calgary and University Technologies International (UTI). CDRD's mission is to bridge the commercialization gap between drug discovery and private investment by providing resources to translate academic discoveries into new medicines. As such, these agreements will provide University of Calgary and UTI investigators with access to CDRD's infrastructure and expertise to assist them in overcoming scientific and project management challenges faced as they work to develop new therapeutics for the treatment of human disease.
"We are pleased to reach this agreement with CDRD, as it will give our medical research community added external support as they look at developing a wide array of innovative medical solutions," said Dr. Jon Meddings, Interim Vice President of Research at the University of Calgary.
"Leveraging CDRD's expertise augments the strategic partnerships necessary for the development of promising drug candidates and their translation into potential cures or treatments for patients," states David Reese, Acting Director, Licensing and Business Development, University Technologies International.
"By working with the leading researchers at the University of Calgary and the commercialization office of UTI, we believe that CDRD's full drug development platform can be effectively utilized to help accelerate and advance the development of their discoveries, taking them one step closer to becoming innovative medical therapeutics," said Karimah Es Sabar, Senior Vice President, Business & Strategic Affairs at CDRD.
New long COVID index highlights five symptom subtypes